MNMD (Mind Medicine (MindMed) Inc. Common Shares)
Insider Trading Activity
Every open-market purchase and sale reported by MNMD officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2025-12-29 | Robert Barrow | Chief Executive Officer | Sell | — | — |
| 2025-12-29 | Mark Sullivan | Chief Legal Officer | Sell | — | — |
| 2025-12-29 | Daniel Karlin | Chief Medical Officer | Sell | — | — |
| 2025-09-26 | Daniel Karlin | Chief Medical Officer | Sell | — | — |
| 2025-09-26 | Robert Barrow | Chief Executive Officer | Sell | — | — |
| 2025-09-26 | Mark Sullivan | Chief Legal Officer | Sell | — | — |
| 2025-06-26 | Mark Sullivan | Chief Legal Officer | Sell | — | — |
| 2025-06-26 | Robert Barrow | Chief Executive Officer | Sell | — | — |
| 2025-06-26 | Daniel Karlin | Chief Medical Officer | Sell | — | — |
| 2025-06-16 | DAVID W GRYSKA | Director | A | — | — |
| 2025-06-16 | Carol A Vallone | Director | A | — | — |
| 2025-06-16 | ROGER CRYSTAL | Director | A | — | — |
| 2025-06-16 | Andreas Krebs | Director | A | — | — |
| 2025-06-16 | Suzanne Louise Bruhn | Director | A | — | — |
| 2025-06-02 | Brandi Roberts | Chief Financial Officer | A | — | — |
| 2025-03-26 | Daniel Karlin | Chief Medical Officer | Sell | — | — |
| 2025-03-26 | Mark Sullivan | Chief Legal Officer | Sell | — | — |
| 2025-03-26 | Robert Barrow | Chief Executive Officer | Sell | — | — |
| 2025-03-26 | Carrie Liao | Chief Accounting Officer | Sell | — | — |
| 2025-03-18 | Matthew T. Wiley | Chief Commercial Officer | A | — | — |
| 2025-03-13 | Carrie Liao | Chief Accounting Officer | A | — | — |
| 2025-03-13 | Daniel Karlin | Chief Medical Officer | A | — | — |
| 2025-03-13 | Robert Barrow | Chief Executive Officer | A | — | — |
| 2025-03-13 | Mark Sullivan | Chief Legal Officer | A | — | — |
| 2024-12-27 | Robert Barrow | Chief Executive Officer | Sell | — | — |
| 2024-12-27 | Carrie Liao | Chief Accounting Officer | Sell | — | — |
| 2024-12-27 | Dan Karlin | Chief Medical Officer | Sell | — | — |
| 2024-12-27 | Mark Sullivan | Chief Legal Officer | Sell | — | — |
| 2024-12-05 | DAVID W GRYSKA | Director | Buy | — | — |
| 2024-09-25 | Robert Barrow | Chief Executive Officer | Sell | — | — |
| 2024-09-25 | Mark Sullivan | Chief Legal Officer | Sell | — | — |
| 2024-09-25 | Dan Karlin | Chief Medical Officer | Sell | — | — |
| 2024-09-25 | Carrie Liao | Chief Accounting Officer | Sell | — | — |
| 2024-08-26 | DAVID W GRYSKA | Director | Buy | — | — |
| 2024-08-22 | Wernli Miri Halperin | Executive President | MIXED | — | — |
| 2024-08-20 | Robert Barrow | Chief Executive Officer | Buy | — | — |
| 2024-06-25 | Mark Sullivan | Chief Legal Officer | Sell | — | — |
| 2024-06-25 | Dan Karlin | Chief Medical Officer | Sell | — | — |
| 2024-06-25 | Robert Barrow | Chief Executive Officer | Sell | — | — |
| 2024-06-12 | Carol A Vallone | Director | A | — | — |
| 2024-06-12 | Andreas Krebs | Director | A | — | — |
| 2024-06-12 | ROGER CRYSTAL | Director | A | — | — |
| 2024-06-12 | Suzanne Louise Bruhn | Director | A | — | — |
| 2024-06-12 | DAVID W GRYSKA | Director | A | — | — |
| 2024-03-26 | Schond L. Greenway | Chief Financial Officer | F | — | — |
| 2024-03-26 | Dan Karlin | Chief Medical Officer | Sell | — | — |
| 2024-03-26 | Robert Barrow | Chief Executive Officer | Sell | — | — |
| 2024-02-29 | Schond L. Greenway | Chief Financial Officer | A | — | — |
| 2024-02-29 | Robert Barrow | Chief Executive Officer | A | — | — |
| 2024-02-29 | Mark Sullivan | Chief Legal Officer | A | — | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| — | Chief Executive Officer | 778,477 | — |
| — | Chief Medical Officer | 425,025 | — |
| — | Chief Legal Officer | 282,576 | — |
| — | Executive President | 235,000 | — |
| — | Chief Financial Officer | 211,057 | — |
| — | Chief Accounting Officer | 144,923 | — |
| — | Chief Legal Officer&Secretary | 80,000 | — |
| — | Director | 19,851 | — |
| — | Director | 19,623 | — |
| — | Director | 19,623 | — |
| — | Director | 16,544 | — |
| — | Director | 15,107 | — |
| — | Director | 10,580 | — |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the MNMD quote page; the site-wide leaderboard is on the insider transactions hub.